Generic Name and Formulations:
Alvimopan 12mg; hard-gelatin caps.
Merck & Co., Inc.
Indications for ENTEREG:
To accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection surgery with primary anastomosis.
Give 12mg 30mins to 5hrs before surgery, then 12mg twice daily starting on 1st post-op day until hospital discharge for up to 7 days; max 15 doses.
Opioid use, at therapeutic doses, for >7 consecutive days prior.
Potential risk of MI with long-term use: for short-term hospital use only.
For short-term hospital use only. Potential risk of MI with long-term use. Severe hepatic impairment, ESRD, complete GI obstruction, pancreatic or gastric anastomosis: not recommended. Mild-to-severe renal impairment or mild-to-moderate hepatic impairment: monitor closely; discontinue if adverse reactions occur. Recent (within week prior to surgery) use of >3 doses of opioids; monitor for GI events. Japanese patients (monitor). Pregnancy (Cat.B). Nursing mothers.
Opioid antagonist (peripheral).
Available only to hospitals that enroll in Entereg Access Support and Education Program (EASE). For more information, and to enroll, call (877) 282-4786.
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D